High-mobility group box 1 and cancer

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1799, Issue 1-2, 2010, Pages 131-140

  Tang, Daolin ^a   Kang, Rui ^a   Zeh III, Herbert J ^a   Lotze, Michael T ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Autophagy; Cancer; CD24; Damage associated molecular pattern molecule DAMP ; Field effect; Hallmarks of cancer; HMGB1; Inflammation; Receptor for advanced glycation endproducts RAGE ; TLR2; TLR4; TLR9

Indexed keywords

3,3',4',5,7 PENTAHYDROXYFLAVONE DIHYDRATE; CISPLATIN; DNA BINDING PROTEIN; ESTROGEN RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEUTRALIZING ANTIBODY; OXALIPLATIN; PROTEIN P53; PROTEIN P73; PYRUVIC ACID DERIVATIVE; QUERCETIN DERIVATIVE; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR REL; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER INVASION; CARCINOGENESIS; CELL FUNCTION; CELL GROWTH; CLINICAL STUDY; COLON CANCER; DISEASE ASSOCIATION; HUMAN; INFLAMMATION; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; METASTASIS; MICROENVIRONMENT; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; STOMACH CANCER; UTERINE CERVIX CANCER; WOUND HEALING IMPAIRMENT;

ANIMALS; CELL NUCLEUS; HMGB1 PROTEIN; HUMANS; NEOPLASMS; NF-KAPPA B; RECEPTORS, ESTROGEN; TUMOR SUPPRESSOR PROTEINS;

EID: 74549175673     PISSN: 18749399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2009.11.014     Document Type: Review

References (158)

1. Goodwin G.H., and Johns E.W. The isolation and purification of the high mobility group (HMG) nonhistone chromosomal proteins. Methods Cell Biol. 16 (1977) 257-267
2. Lotze M.T., and Tracey K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev., Immunol. 5 (2005) 331-342
3. Muller S., Scaffidi P., Degryse B., Bonaldi T., Ronfani L., Agresti A., Beltrame M., and Bianchi M.E. New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J. 20 (2001) 4337-4340
4. Dong X.D., Ito N., Lotze M.T., Demarco R.A., Popovic P., Shand S.H., Watkins S., Winikoff S., Brown C.K., Bartlett D.L., and Zeh III H.J. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J. Immunother. 30 2007 (1997) 596-606
5. Ellerman J.E., Brown C.K., de Vera M., Zeh H.J., Billiar T., Rubartelli A., and Lotze M.T. Masquerader: high mobility group box-1 and cancer. Clin. Cancer Res. 13 (2007) 2836-2848
6. Scaffidi P., Misteli T., and Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418 (2002) 191-195
7. Tian J., Avalos A.M., Mao S.Y., Chen B., Senthil K., Wu H., Parroche P., Drabic S., Golenbock D., Sirois C., Hua J., An L.L., Audoly L., La Rosa G., Bierhaus A., Naworth P., Marshak-Rothstein A., Crow M.K., Fitzgerald K.A., Latz E., Kiener P.A., and Coyle A.J. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8 (2007) 487-496
8. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., Frazier A., Yang H., Ivanova S., Borovikova L., Manogue K.R., Faist E., Abraham E., Andersson J., Andersson U., Molina P.E., Abumrad N.N., Sama A., and Tracey K.J. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285 (1999) 248-251
9. Wang H., Yang H., and Tracey K.J. Extracellular role of HMGB1 in inflammation and sepsis. J. Intern. Med. 255 (2004) 320-331
10. Tsung A., Sahai R., Tanaka H., Nakao A., Fink M.P., Lotze M.T., Yang H., Li J., Tracey K.J., Geller D.A., and Billiar T.R. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J. Exp. Med. 201 (2005) 1135-1143
11. Andersson U., and Tracey K.J. HMGB1 as a mediator of necrosis-induced inflammation and a therapeutic target in arthritis. Rheum. Dis. Clin. North Am. 30 (2004) 627-637 xi
12. Tang D., Kang R., Cao L., Zhang G., Yu Y., Xiao W., Wang H., and Xiao X. A pilot study to detect high mobility group box 1 and heat shock protein 72 in cerebrospinal fluid of pediatric patients with meningitis. Crit. Care Med. 36 (2008) 291-295
13. Qi M.L., Tagawa K., Enokido Y., Yoshimura N., Wada Y., Watase K., Ishiura S., Kanazawa I., Botas J., Saitoe M., Wanker E.E., and Okazawa H. Proteome analysis of soluble nuclear proteins reveals that HMGB1/2 suppress genotoxic stress in polyglutamine diseases. Nat. Cell Biol. 9 (2007) 402-414
14. Enokido Y., Yoshitake A., Ito H., and Okazawa H. Age-dependent change of HMGB1 and DNA double-strand break accumulation in mouse brain. Biochem. Biophys. Res. Commun. 376 (2008) 128-133
15. Sparvero L.J., Asafu-Adjei D., Kang R., Tang D., Amin N., Im J., Rutledge R., Lin B., Amoscato A.A., Zeh H.J., and Lotze M.T. RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. J. Transl. Med. 7 (2009) 17
16. Lotze M.T., and DeMarco R.A. Dealing with death: HMGB1 as a novel target for cancer therapy. Curr. Opin. Investig. Drugs 4 (2003) 1405-1409
17. Land W., Schneeberger H., Schleibner S., Illner W.D., Abendroth D., Rutili G., Arfors K.E., and Messmer K. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation 57 (1994) 211-217
18. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12 (1994) 991-1045
19. Bustin M., Lehn D.A., and Landsman D. Structural features of the HMG chromosomal proteins and their genes. Biochim. Biophys. Acta 1049 (1990) 231-243
20. Alexandrova E.A., and Beltchev B.G. Differences between HMG1 proteins isolated from normal and tumour cells. Biochim. Biophys. Acta 915 (1987) 399-405
21. Alexandrova E.A., and Beltchev B.G. Acetylated HMG1 protein interacts specifically with homologous DNA polymerase alpha in vitro. Biochem. Biophys. Res. Commun. 154 (1988) 918-927
22. Bonaldi T., Talamo F., Scaffidi P., Ferrera D., Porto A., Bachi A., Rubartelli A., Agresti A., and Bianchi M.E. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22 (2003) 5551-5560
23. Kang H.J., Lee H., Choi H.J., Youn J.H., Shin J.S., Ahn Y.H., Yoo J.S., Paik Y.K., and Kim H. Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers. Lab. Invest. 89 (2009) 948-959
24. Ito I., Fukazawa J., and Yoshida M. Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J. Biol. Chem. 282 (2007) 16336-16344
25. Oh Y.J., Youn J.H., Ji Y., Lee S.E., Lim K.J., Choi J.E., and Shin J.S. HMGB1 is phosphorylated by classical protein kinase C and is secreted by a calcium-dependent mechanism. J. Immunol. 182 (2009) 5800-5809
26. Tang D., Shi Y., Kang R., Li T., Xiao W., Wang H., and Xiao X. Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J. Leukoc. Biol. 81 (2007) 741-747
27. Choi Y.R., Kim H., Kang H.J., Kim N.G., Kim J.J., Park K.S., Paik Y.K., and Kim H.O. Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res. 63 (2003) 2188-2193
28. Volp K., Brezniceanu M.L., Bosser S., Brabletz T., Kirchner T., Gottel D., Joos S., and Zornig M. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 55 (2006) 234-242
29. Hao Q., Du X.Q., Fu X., and Tian J. Expression and clinical significance of HMGB1 and RAGE in cervical squamous cell carcinoma. Zhonghua Zhongliu Zazhi 30 (2008) 292-295
30. Ishiguro H., Nakaigawa N., Miyoshi Y., Fujinami K., Kubota Y., and Uemura H. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 64 (2005) 92-100
31. Poser I., Golob M., Buettner R., and Bosserhoff A.K. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol. Cell. Biol. 23 (2003) 2991-2998
32. He Q., Liang C.H., and Lippard S.J. Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 5768-5772
33. Sharma A., Ray R., and Rajeswari M.R. Overexpression of high mobility group (HMG) B1 and B2 proteins directly correlates with the progression of squamous cell carcinoma in skin. Cancer Investig. 26 (2008) 843-851
34. Uramoto H., Izumi H., Nagatani G., Ohmori H., Nagasue N., Ise T., Yoshida T., Yasumoto K., and Kohno K. Physical interaction of tumour suppressor p53/p73 with CCAAT-binding transcription factor 2 (CTF2) and differential regulation of human high-mobility group 1 (HMG1) gene expression. Biochem. J. 371 (2003) 301-310
35. Rothermund K., Rogulski K., Fernandes E., Whiting A., Sedivy J., Pu L., and Prochownik E.V. C-Myc-independent restoration of multiple phenotypes by two C-Myc target genes with overlapping functions. Cancer Res. 65 (2005) 2097-2107
36. Liu J., Liu Y., Zhang H., Chen G., Wang K., and Xiao X. KLF4 promotes the expression, translocation, and releas eof HMGB1 in RAW264.7 macrophages in response to LPS. Shock 30 (2008) 260-266
37. Lange S.S., and Vasquez K.M. HMGB1: the jack-of-all-trades protein is a master DNA repair mechanic. Mol. Carcinog. 48 (2009) 571-580
38. Jantzen H.M., Admon A., Bell S.P., and Tjian R. Nucleolar transcription factor hUBF contains a DNA-binding motif with homology to HMG proteins. Nature 344 (1990) 830-836
39. Ohndorf U.M., Rould M.A., He Q., Pabo C.O., and Lippard S.J. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature 399 (1999) 708-712
40. Yanai H., Ban T., Wang Z., Choi M.K., Kawamura T., Negishi H., Nakasato M., Lu Y., Hangai S., Koshiba R., Savitsky D., Ronfani L., Akira S., Bianchi M.E., Honda K., Tamura T., Kodama T., and Taniguchi T. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 462 (2009) 99-103
41. Topalova D., Ugrinova I., Pashev I.G., and Pasheva E.A. HMGB1 protein inhibits DNA replication in vitro: a role of the acetylation and the acidic tail. Int. J. Biochem. Cell Biol. 40 (2008) 1536-1542
42. Jayaraman L., Moorthy N.C., Murthy K.G., Manley J.L., Bustin M., and Prives C. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev. 12 (1998) 462-472
43. McKinney K., and Prives C. Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol. Cell. Biol. 22 (2002) 6797-6808
44. Banerjee S., and Kundu T.K. The acidic C-terminal domain and A-box of HMGB-1 regulates p53-mediated transcription. Nucleic Acids Res. 31 (2003) 3236-3247
45. Stros M., Muselikova-Polanska E., Pospisilova S., and Strauss F. High-affinity binding of tumor-suppressor protein p53 and HMGB1 to hemicatenated DNA loops. Biochemistry 43 (2004) 7215-7225
46. Livesey K.M., Tang D., Zeh H.J., and Lotze M.T. Not just nuclear proteins: 'novel' autophagy cancer treatment targets - p53 and HMGB1. Curr. Opin. Investig. Drugs 9 (2008) 1259-1263
47. Stros M., Ozaki T., Bacikova A., Kageyama H., and Nakagawara A. HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J. Biol. Chem. 277 (2002) 7157-7164
48. Dintilhac A., and Bernues J. HMGB1 interacts with many apparently unrelated proteins by recognizing short amino acid sequences. J. Biol. Chem. 277 (2002) 7021-7028
49. Jiao Y., Wang H.C., and Fan S.J. Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol. Sin. 28 (2007) 1957-1967
50. Brickman J.M., Adam M., and Ptashne M. Interactions between an HMG-1 protein and members of the Rel family. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 10679-10683
51. Agresti A., Lupo R., Bianchi M.E., and Muller S. HMGB1 interacts differentially with members of the Rel family of transcription factors. Biochem. Biophys. Res. Commun. 302 (2003) 421-426
52. El Marzouk S., Gahattamaneni R., Joshi S.R., and Scovell W.M. The plasticity of estrogen receptor-DNA complexes: binding affinity and specificity of estrogen receptors to estrogen response element half-sites separated by variant spacers. J. Steroid Biochem. Mol. Biol. 110 (2008) 186-195
53. Das D., Peterson R.C., and Scovell W.M. High mobility group B proteins facilitate strong estrogen receptor binding to classical and half-site estrogen response elements and relax binding selectivity. Mol. Endocrinol. 18 (2004) 2616-2632
54. Zhang C.C., Krieg S., and Shapiro D.J. HMG-1 stimulates estrogen response element binding by estrogen receptor from stably transfected HeLa cells. Mol. Endocrinol. 13 (1999) 632-643
55. Verrier C.S., Roodi N., Yee C.J., Bailey L.R., Jensen R.A., Bustin M., and Parl F.F. High-mobility group (HMG) protein HMG-1 and TATA-binding protein-associated factor TAF(II)30 affect estrogen receptor-mediated transcriptional activation. Mol. Endocrinol. 11 (1997) 1009-1019
56. Krynetski E.Y., Krynetskaia N.F., Bianchi M.E., and Evans W.E. A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogues. Cancer Res. 63 (2003) 100-106
57. Imamura T., Izumi H., Nagatani G., Ise T., Nomoto M., Iwamoto Y., and Kohno K. Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein. J. Biol. Chem. 276 (2001) 7534-7540
58. Zhang G., Kobayashi T., Kamitani W., Komoto S., Yamashita M., Baba S., Yanai H., Ikuta K., and Tomonaga K. Borna disease virus phosphoprotein represses p53-mediated transcriptional activity by interference with HMGB1. J. Virol. 77 (2003) 12243-12251
59. Krynetskaia N., Xie H., Vucetic S., Obradovic Z., and Krynetskiy E. High mobility group protein B1 is an activator of apoptotic response to antimetabolite drugs. Mol. Pharmacol. 73 (2008) 260-269
60. Krynetskaia N.F., Phadke M.S., Jadhav S.H., and Krynetskiy E.Y. Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol. Cancer Ther. 8 (2009) 864-872
61. Melino G., De Laurenzi V., and Vousden K.H. p73: friend or foe in tumorigenesis. Nat. Rev., Cancer 2 (2002) 605-615
62. Kepp O., Tesniere A., Schlemmer F., Michaud M., Senovilla L., Zitvogel L., and Kroemer G. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 14 (2009) 364-375
63. Bianchi M.E. HMGB1 loves company. J. Leukoc. Biol. 86 (2009) 573-576
64. Lotze M.T., Deisseroth A., and Rubartelli A. Damage associated molecular pattern molecules. Clin. Immunol. 124 (2007) 1-4
65. Dong Xda E., Ito N., Lotze M.T., Demarco R.A., Popovic P., Shand S.H., Watkins S., Winikoff S., Brown C.K., Bartlett D.L., and Zeh III H.J. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J. Immunother. 30 (2007) 596-606
66. Bustin M. At the crossroads of necrosis and apoptosis: signaling to multiple cellular targets by HMGB1. Sci. STKE 2002 (2002) pe39
67. Ito N., Demarco R.A., Mailliard R.B., Han J., Rabinowich H., Kalinski P., Stolz D.B., Zeh III H.J., and Lotze M.T. Cytolytic cells induce HMGB1 release from melanoma cell lines. J. Leukoc. Biol. 81 (2007) 75-83
68. Thorburn J., Frankel A.E., and Thorburn A. Regulation of HMGB1 release by autophagy. Autophagy 5 (2009) 247-249
69. Thorburn J., Horita H., Redzic J., Hansen K., Frankel A.E., and Thorburn A. Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ. 16 (2009) 175-183
70. Tang D., Kang R., Xiao W., Zhang H., Lotze M.T., Wang H., and Xiao X. Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function. Am. J. Respir. Cell. Mol. Biol. 41 6 (2009 Dec) 651-660 PubMed PMID: 19265175; PubMed Central PMCID: PMC2784404 (Electronic publication ahead of print, 2009 Mar 5)
71. Cardinal J., Pan P., Dhupar R., Ross M., Nakao A., Lotze M., Billiar T., Geller D., and Tsung A. Cisplatin prevents high mobility group box 1 release and is protective in a murine model of hepatic ischemia/reperfusion injury. Hepatology 50 (2009) 565-574
72. Brusa D., Migliore E., Garetto S., Simone M., and Matera L. Immunogenicity of 56 degrees C and UVC-treated prostate cancer is associated with release of HSP70 and HMGB1 from necrotic cells. Prostate 69 (2009) 1343-1352
73. Kazama H., Ricci J.E., Herndon J.M., Hoppe G., Green D.R., and Ferguson T.A. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 29 (2008) 21-32
74. Qin S., Wang H., Yuan R., Li H., Ochani M., Ochani K., Rosas-Ballina M., Czura C.J., Huston J.M., Miller E., Lin X., Sherry B., Kumar A., Larosa G., Newman W., Tracey K.J., and Yang H. Role of HMGB1 in apoptosis-mediated sepsis lethality. J. Exp. Med. 203 (2006) 1637-1642
75. Campana L., Bosurgi L., and Rovere-Querini P. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr. Opin. Immunol. 20 (2008) 518-523
76. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M.C., Ullrich E., Saulnier P., Yang H., Amigorena S., Ryffel B., Barrat F.J., Saftig P., Levi F., Lidereau R., Nogues C., Mira J.P., Chompret A., Joulin V., Clavel-Chapelon F., Bourhis J., Andre F., Delaloge S., Tursz T., Kroemer G., and Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13 (2007) 1050-1059
77. Apetoh L., Ghiringhelli F., Tesniere A., Criollo A., Ortiz C., Lidereau R., Mariette C., Chaput N., Mira J.P., Delaloge S., Andre F., Tursz T., Kroemer G., and Zitvogel L. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol. Rev. 220 (2007) 47-59
78. Curtin J.F., Liu N., Candolfi M., Xiong W., Assi H., Yagiz K., Edwards M.R., Michelsen K.S., Kroeger K.M., Liu C., Muhammad A.K., Clark M.C., Arditi M., Comin-Anduix B., Ribas A., Lowenstein P.R., and Castro M.G. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 6 (2009) e10
79. Liang X., Chavez A.R., Schapiro N.E., Loughran P., Thorne S.H., Amoscato A.A., Zeh H.J., Beer-Stolz D., Lotze M.T., and de Vera M.E. Ethyl pyruvate administration inhibits hepatic tumor growth. J. Leukoc. Biol. 86 (2009) 599-607
80. Chen G.Y., Tang J., Zheng P., and Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 323 (2009) 1722-1725
81. Taguchi A., Blood D.C., del Toro G., Canet A., Lee D.C., Qu W., Tanji N., Lu Y., Lalla E., Fu C., Hofmann M.A., Kislinger T., Ingram M., Lu A., Tanaka H., Hori O., Ogawa S., Stern D.M., and Schmidt A.M. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405 (2000) 354-360
82. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
83. Mantovani A. Cancer: inflaming metastasis. Nature 457 (2009) 36-37
84. Mantovani A., Allavena P., Sica A., and Balkwill F. Cancer-related inflammation. Nature 454 (2008) 436-444
85. Vakkila J., and Lotze M.T. Inflammation and necrosis promote tumour growth. Nat. Rev., Immunol. 4 (2004) 641-648
86. Guerin R., Arseneault G., Dumont S., and Rokeach L.A. Calnexin is involved in apoptosis induced by endoplasmic reticulum stress in the fission yeast. Mol. Biol. Cell 19 (2008) 4404-4420
87. Brezniceanu M.L., Volp K., Bosser S., Solbach C., Lichter P., Joos S., and Zornig M. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J. 17 (2003) 1295-1297
88. Gnanasekar M., Thirugnanam S., and Ramaswamy K. Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Int. J. Oncol. 34 (2009) 425-431
89. Yu Y., Xie M., He Y.L., Xu W.Q., Zhu S., and Cao L.Z. Role of high mobility group box 1 in adriamycin-induced apoptosis in leukemia K562 cells. Ai Zheng 27 (2008) 929-933
90. Xie M., Kang R., Yu Y., Zhu S., He Y.L., Xu W.Q., Tang D.L., and Cao L.Z. [Enhancive effect of HMGB1 gene silence on adriamycin-induced apoptosis in K562/A02 drug resistance leukemia cells]. Zhonghua Xue Ye Xue Za Zhi 29 (2008) 549-552
91. Kang R., Tang D., Schapiro N.E., Livesey K.M., Farkas A., Loughran P., Bierhaus A., Lotze M.T., and Zeh H.J. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ. (2009 Oct 16) PubMed PMID: 19834494 (Electronic publication ahead of print)
92. Barnes K.R., Kutikov A., and Lippard S.J. Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. Chem. Biol. 11 (2004) 557-564
93. Lange S.S., Mitchell D.L., and Vasquez K.M. High mobility group protein B1 enhances DNA repair and chromatin modification after DNA damage. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 10320-10325
94. Schlueter C., Weber H., Meyer B., Rogalla P., Roser K., Hauke S., and Bullerdiek J. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am. J. Pathol. 166 (2005) 1259-1263
95. van Beijnum J.R., Buurman W.A., and Griffioen A.W. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 11 (2008) 91-99
96. Wake H., Mori S., Liu K., Takahashi H.K., and Nishibori M. Histidine-rich glycoprotein inhibited high mobility group box 1 in complex with heparin-induced angiogenesis in matrigel plug assay. Eur. J. Pharmacol. 623 (2009) 89-95
97. Sasahira T., Kirita T., Bhawal U.K., Ikeda M., Nagasawa A., Yamamoto K., and Kuniyasu H. The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Arch. 450 (2007) 287-295
98. van Beijnum J.R., Dings R.P., van der Linden E., Zwaans B.M., Ramaekers F.C., Mayo K.H., and Griffioen A.W. Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 108 (2006) 2339-2348
99. Wang Z.T., Yao Y.M., and Sheng Z.Y. Effect of high mobility group box 1 protein on proliferation and apoptosis and balance between Th1/Th2 and Tc1/Tc2 of lymphocytes in vitro. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 24 (2008) 324-327
100. Palumbo R., Sampaolesi M., De Marchis F., Tonlorenzi R., Colombetti S., Mondino A., Cossu G., and Bianchi M.E. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J. Cell Biol. 164 (2004) 441-449
101. Kuniyasu H., Yano S., Sasaki T., Sasahira T., Sone S., and Ohmori H. Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages. Am. J. Pathol. 166 (2005) 751-760
102. Blasco M.A. Telomeres and human disease: ageing, cancer and beyond. Nat. Rev., Genet. 6 (2005) 611-622
103. Stewart S.A., and Weinberg R.A. Telomeres: cancer to human aging. Annu. Rev. Cell Dev. Biol. 22 (2006) 531-557
104. Calogero S., Grassi F., Aguzzi A., Voigtlander T., Ferrier P., Ferrari S., and Bianchi M.E. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat. Genet. 22 (1999) 276-280
105. Pallier C., Scaffidi P., Chopineau-Proust S., Agresti A., Nordmann P., Bianchi M.E., and Marechal V. Association of chromatin proteins high mobility group box (HMGB) 1 and HMGB2 with mitotic chromosomes. Mol. Biol. Cell 14 (2003) 3414-3426
106. Kuniyasu H., Oue N., Wakikawa A., Shigeishi H., Matsutani N., Kuraoka K., Ito R., Yokozaki H., and Yasui W. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J. Pathol. 196 (2002) 163-170
107. Sasahira T., Akama Y., Fujii K., and Kuniyasu H. Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch. 446 (2005) 411-415
108. Liu L., Zhao L., Zhang Y., Zhang Q., and Ding Y. Proteomic analysis of Tiam1-mediated metastasis in colorectal cancer. Cell Biol. Int. 31 (2007) 805-814
109. Harada O., Suga T., Suzuki T., Nakamoto K., Kobayashi M., Nomiyama T., Nadano D., Ohyama C., Fukuda M.N., and Nakayama J. The role of trophinin, an adhesion molecule unique to human trophoblasts, in progression of colorectal cancer. Int. J. Cancer 121 (2007) 1072-1078
110. Kuniyasu H., Chihara Y., and Kondo H. Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int. J. Cancer 104 (2003) 722-727
111. Kuniyasu H., Sasaki T., Sasahira T., Ohmori H., and Takahashi T. Depletion of tumor-infiltrating macrophages is associated with amphoterin expression in colon cancer. Pathobiology 71 (2004) 129-136
112. Kusume A., Sasahira T., Luo Y., Isobe M., Nakagawa N., Tatsumoto N., Fujii K., Ohmori H., and Kuniyasu H. Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer. Pathobiology 76 (2009) 155-162
113. de Visser K.E., and Coussens L.M. The inflammatory tumor microenvironment and its impact on cancer development. Contrib. Microbiol. 13 (2006) 118-137
114. Lotze M.T., Zeh H.J., Rubartelli A., Sparvero L.J., Amoscato A.A., Washburn N.R., Devera M.E., Liang X., Tor M., and Billiar T. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol. Rev. 220 (2007) 60-81
115. Zeh III H.J., and Lotze M.T. Addicted to death: invasive cancer and the immune response to unscheduled cell death. J. Immunother. 28 (2005) 1-9
116. Faham A., Bennett D., and Altin J.G. Liposomal Ag engrafted with peptides of sequence derived from HMGB1 induce potent Ag-specific and anti-tumour immunity. Vaccine 27 (2009) 5846-5854
117. Liu G., Wang J., Park Y.J., Tsuruta Y., Lorne E.F., Zhao X., and Abraham E. High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine. J. Immunol. 181 (2008) 4240-4246
118. Yoon S., Lee J.Y., Yoon B.K., Bae D.S., and Choi D.S. Effects of HMGB-1 overexpression on cell-cycle progression in MCF-7 cells. J. Korean Med. Sci. 19 (2004) 321-326
119. Voit R., Schafer K., and Grummt I. Mechanism of repression of RNA polymerase I transcription by the retinoblastoma protein. Mol. Cell. Biol. 17 (1997) 4230-4237
120. Park J.S., Arcaroli J., Yum H.K., Yang H., Wang H., Yang K.Y., Choe K.H., Strassheim D., Pitts T.M., Tracey K.J., and Abraham E. Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am. J. Physiol., Cell Physiol. 284 (2003) C870-C879
121. Fan J., Li Y., Levy R.M., Fan J.J., Hackam D.J., Vodovotz Y., Yang H., Tracey K.J., Billiar T.R., and Wilson M.A. Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: role of HMGB1-TLR4 signaling. J. Immunol. 178 (2007) 6573-6580
122. Degryse B., Bonaldi T., Scaffidi P., Muller S., Resnati M., Sanvito F., Arrigoni G., and Bianchi M.E. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J. Cell Biol. 152 (2001) 1197-1206
123. Park J.S., Svetkauskaite D., He Q., Kim J.Y., Strassheim D., Ishizaka A., and Abraham E. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279 (2004) 7370-7377
124. Kalinina N., Agrotis A., Antropova Y., DiVitto G., Kanellakis P., Kostolias G., Ilyinskaya O., Tararak E., and Bobik A. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 2320-2325
125. Tang D., Kang R., Xiao W., Wang H., Calderwood S.K., and Xiao X. The anti-inflammatory effects of heat shock protein 72 involve inhibition of high-mobility-group box 1 release and proinflammatory function in macrophages. J. Immunol. 179 (2007) 1236-1244
126. Tang D., Kang R., Xiao W., Jiang L., Liu M., Shi Y., Wang K., Wang H., and Xiao X. Nuclear heat shock protein 72 as a negative regulator of oxidative stress (hydrogen peroxide)-induced HMGB1 cytoplasmic translocation and release. J. Immunol. 178 (2007) 7376-7384
127. Tang D., Shi Y., Jang L., Wang K., Xiao W., and Xiao X. Heat shock response inhibits release of high mobility group box 1 protein induced by endotoxin in murine macrophages. Shock 23 (2005) 434-440
128. Kuniyasu H., Chihara Y., and Takahashi T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol. Rep. 10 (2003) 445-448
129. Kijanka G.S., Hector S., Kay E.W., Murray F., Cummins R., Murphy D., Maccraith B.D., Prehn J.H., and Kenny D. Human IgG antibody profiles differentiate between symptomatic patients with and without colorectal cancer. Gut (2009 Oct 13) PubMed PMID: 19828471 (Electronic publication ahead of print)
130. Flohr A.M., Rogalla P., Meiboom M., Borrmann L., Krohn M., Thode-Halle B., and Bullerdiek J. Variation of HMGB1 expression in breast cancer. Anticancer Res. 21 (2001) 3881-3885
131. Shang G.H., Jia C.Q., Tian H., Xiao W., Li Y., Wang A.H., Dong L., and Lin D.J. Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Respir. Med. 103 12 (2009 Dec) 1949-1953 PubMed PMID: 19535236 (Electronic publication ahead of print, 2009 Jun 17)
132. Shen X., Hong L., Sun H., Shi M., and Song Y. The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer. Oncol. Rep. 22 (2009) 535-539
133. Kuniyasu H., Chihara Y., Kondo H., Ohmori H., and Ukai R. Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol. Rep. 10 (2003) 1863-1868
134. Sheng X., Du X., Zhang X., Li D., Lu C., Li Q., Ma Z., Song Q., and Wang C. Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels. Croat. Med. J. 50 (2009) 455-464
135. Chung H.W., Lee S.G., Kim H., Hong D.J., Chung J.B., Stroncek D., and Lim J.B. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J. Transl. Med. 7 (2009) 38
136. Cheng B.Q., Jia C.Q., Liu C.T., Lu X.F., Zhong N., Zhang Z.L., Fan W., and Li Y.Q. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig. Liver Dis. 40 (2008) 446-452
137. Meyer A., Staratschek-Jox A., Springwald A., Wenk H., Wolf J., Wickenhauser C., and Bullerdiek J. Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1. Leuk. Lymphoma 49 (2008) 1184-1189
138. Kang R., Tang D.L., Cao L.Z., Yu Y., Zhang G.Y., and Xiao X.Z. High mobility group box 1 is increased in children with acute lymphocytic leukemia and stimulates the release of tumor necrosis factor-alpha in leukemic cell. Zhonghua Er Ke Za Zhi 45 (2007) 329-333
139. Maeda S., Hikiba Y., Shibata W., Ohmae T., Yanai A., Ogura K., Yamada S., and Omata M. Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochem. Biophys. Res. Commun. 360 (2007) 394-400
140. Hanford L.E., Enghild J.J., Valnickova Z., Petersen S.V., Schaefer L.M., Schaefer T.M., Reinhart T.A., and Oury T.D. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J. Biol. Chem. 279 (2004) 50019-50024
141. Tesarova P., Kalousova M., Jachymova M., Mestek O., Petruzelka L., and Zima T. Receptor for advanced glycation end products (RAGE)-soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Investig. 25 (2007) 720-725
142. Liliensiek B., Weigand M.A., Bierhaus A., Nicklas W., Kasper M., Hofer S., Plachky J., Grone H.J., Kurschus F.C., Schmidt A.M., Yan S.D., Martin E., Schleicher E., Stern D.M., Hammerling G.G., Nawroth P.P., and Arnold B. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 113 (2004) 1641-1650
143. Ulloa L., Ochani M., Yang H., Tanovic M., Halperin D., Yang R., Czura C.J., Fink M.P., and Tracey K.J. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 12351-12356
144. Dave S.H., Tilstra J.S., Matsuoka K., Li F., DeMarco R.A., Beer-Stolz D., Sepulveda A.R., Fink M.P., Lotze M.T., and Plevy S.E. Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J. Leukoc. Biol. 86 (2009) 633-643
145. Chung K.Y., Park J.J., and Kim Y.S. The role of high-mobility group box-1 in renal ischemia and reperfusion injury and the effect of ethyl pyruvate. Transplant. Proc. 40 (2008) 2136-2138
146. Lim S.C., Choi J.E., Kim C.H., Duong H.Q., Jeong G.A., Kang H.S., and Han S.I. Ethyl pyruvate induces necrosis-to-apoptosis switch and inhibits high mobility group box protein 1 release in A549 lung adenocarcinoma cells. Int. J. Mol. Med. 20 (2007) 187-192
147. Zong W.X., Ditsworth D., Bauer D.E., Wang Z.Q., Thompson C.B., and Alkylating D. damage stimulates a regulated form of necrotic cell death. Genes Dev. 18 (2004) 1272-1282
148. Li G., Liu W., and Frenz D. Cisplatin ototoxicity to the rat inner ear: a role for HMG1 and iNOS. Neurotoxicology 27 (2006) 22-30
149. Ostberg T., Wahamaa H., Palmblad K., Ito N., Stridh P., Shoshan M., Lotze M.T., Harris H.E., and Andersson U. Oxaliplatin retains HMGB1 intranuclearly and ameliorates collagen type II-induced arthritis. Arthritis Res. Ther. 10 (2008) R1
150. Sharma A., Ramanjaneyulu A., Ray R., and Rajeswari M.R. Involvement of high mobility group B proteins in cisplatin-induced cytotoxicity in squamous cell carcinoma of skin. DNA Cell Biol. 28 (2009) 311-318
151. Dias A.S., Porawski M., Alonso M., Marroni N., Collado P.S., and Gonzalez-Gallego J. Quercetin decreases oxidative stress, NF-kappaB activation, and iNOS overexpression in liver of streptozotocin-induced diabetic rats. J. Nutr. 135 (2005) 2299-2304
152. Manjeet K.R., and Ghosh B. Quercetin inhibits LPS-induced nitric oxide and tumor necrosis factor-alpha production in murine macrophages. Int. J. Immunopharmacol. 21 (1999) 435-443
153. Abd El-Gawad H.M., and Khalifa A.E. Quercetin, coenzyme Q10, and L-canavanine as protective agents against lipid peroxidation and nitric oxide generation in endotoxin-induced shock in rat brain. Pharmacol. Res. 43 (2001) 257-263
154. Liu J.J., Song C.W., Yue Y., Duan C.G., Yang J., He T., and He Y.Z. Quercetin inhibits LPS-induced delay in spontaneous apoptosis and activation of neutrophils. Inflamm. Res. 54 (2005) 500-507
155. Lamson D.W., and Brignall M.S. Antioxidants and cancer: Part 3. Quercetin. Altern. Med. Rev. 5 (2000) 196-208
156. Avila M.A., Velasco J.A., Cansado J., and Notario V. Quercetin mediates the down-regulation of mutant p53 in the human breast cancer cell line MDA-MB468. Cancer Res. 54 (1994) 2424-2428
157. Chien S.Y., Wu Y.C., Chung J.G., Yang J.S., Lu H.F., Tsou M.F., Wood W.G., Kuo S.J., and Chen D.R. Quercetin-induced apoptosis acts through mitochondrial- and caspase-3-dependent pathways in human breast cancer MDA-MB-231 cells. Human Exp. Toxicol. 28 (2009) 493-503
158. Wang H., Zhu S., Zhou R., Li W., and Sama A.E. Therapeutic potential of HMGB1-targeting agents in sepsis. Expert. Rev. Mol. Med. 10 (2008) e32